MEDX Xelerator

VeinWay is a medical device company focused on developing innovative solutions for chronic venous occlusions caused by blockages or disease. The firm has created a specialized catheter designed to assist physicians in recanalizing obstructed veins, facilitating the restoration of blood flow to the heart. This platform provides a dedicated tool that enables medical professionals to navigate complex blockages that were previously deemed uncrossable, thereby improving the efficiency and safety of venous treatments. By addressing the challenges associated with chronic venous disease, VeinWay aims to transform the approach to treating these conditions.

Exero Medical is a medical device manufacturing company based in Or Yehuda, Israel, founded in 2018. The company specializes in the development of a biodegradable wireless sensor aimed at the early detection of anastomotic leaks following gastrointestinal surgery. This innovative device enhances patient recovery by providing real-time monitoring of the anastomosis area, allowing healthcare professionals to identify potential leaks and intervene promptly, thereby reducing the risk of complications and shortening hospital stays.

Append Medical is focused on developing a next-generation transcatheter Left Atrial Appendage (LAA) closure system, aimed at preventing strokes by mitigating the risk of blood clot leakage to the brain. Currently in the pre-clinical in-vivo trial phase, the company's innovative approach involves tissue invagination and closure by suture, rather than traditional implants. This method is designed to simplify the treatment of atrial fibrillation while minimizing the presence of foreign materials at the closure site, thereby reducing the risk of device-related thromboembolism. The LAA closure market is anticipated to grow significantly, with estimates suggesting it could reach $25 billion in the coming years. Append Medical is also a participant in MEDX Xelerator, a medtech incubator supported by various industry leaders.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

Synchrony Medical is a clinical stage medical device company focused on developing innovative solutions for respiratory therapy. The company is creating LibAirty, a next-generation airway clearance system intended for home use. This device aims to assist patients with chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), by enabling them to maintain clear lungs through a brief, effective daily treatment. In addition to its airway clearance capabilities, the device incorporates remote monitoring features, allowing for tailored and adaptive home therapy that enhances lung function and facilitates airway clearance.

Dimoveo Medical specializes in the development of innovative technologies for internal body cavity disinfection, specifically targeting implants without the need for their removal. The company utilizes an ultrasound-based approach that employs nanoparticles, which strike the implant at high velocities to effectively clean the surface while preserving its integrity. This technology is particularly beneficial for patients undergoing orthopedic procedures, such as knee replacements, as it helps reduce the risk of infection and the potential need for revision surgeries. By enhancing protocols for in-body surface and implant cleaning, Dimoveo Medical aims to improve patient outcomes in surgical settings.

PatenSee is a clinical-stage medical device company founded in 2019 in Or Yehuda, Central. The company has developed an innovative contactless surveillance system that aims to detect early signs of asymptomatic vascular stenosis in hemodialysis patients. Utilizing advanced multi-modal imaging technologies and machine learning, PatenSee's system is designed to integrate smoothly into clinical workflows. This technology enables healthcare teams to identify early indications of vascular access stenosis, facilitating timely and cost-effective interventions. By safeguarding patients' hemodialysis lifelines, PatenSee enhances the quality of care and aims to extend life expectancy for individuals undergoing treatment.